CORRESP Filing
PDS Biotechnology Corp
Date: June 6, 2025 · CIK: 0001472091 · Accession: 0001140361-25-021742
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287588
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell Registration Statement on Form S-3 Filed May 27, 2025 File 333-287588 Acceleration Request
RE:
Dear Mr. Campbell:
With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of PDS Biotechnology Corporation (the “Company”), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to Tuesday, June 10, 2025, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, DLA Piper LLP (US), request by telephone that such Registration Statement be declared effective at some other time.
The cooperation of the staff in meeting the timetable described above is very much appreciated.
Please call Fahd Riaz of DLA Piper LLP (US), counsel to the Company, at (215) 656-3316, with any comments or questions regarding the Registration Statement.
Very truly yours,
PDS Biotechnology Corporation
Show Raw Text
CORRESP 1 filename1.htm PDS BIOTECHNOLOGY CORPORATION 303A College Road East Princeton, NJ 08540 June 6, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attention: Alan Campbell RE: PDS Biotechnology Corporation Registration Statement on Form S-3 Filed May 27, 2025 File 333-287588 Acceleration Request Dear Mr. Campbell: With respect to the above-referenced Registration Statement on Form S-3 (the “Registration Statement”), and pursuant to Rule 461 of Regulation C promulgated under the Securities Act of 1933, as amended, the undersigned hereby respectfully requests, on behalf of PDS Biotechnology Corporation (the “Company”), that the Securities and Exchange Commission accelerate the effective date of the Registration Statement to Tuesday, June 10, 2025, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter, unless we or our outside counsel, DLA Piper LLP (US), request by telephone that such Registration Statement be declared effective at some other time. The cooperation of the staff in meeting the timetable described above is very much appreciated. Please call Fahd Riaz of DLA Piper LLP (US), counsel to the Company, at (215) 656-3316, with any comments or questions regarding the Registration Statement. Very truly yours, PDS Biotechnology Corporation /s/ Frank Bedu-Addo Frank Bedu-Addo Chief Executive Officer cc: Patrick O’Malley, Esq., DLA Piper LLP (US) Dylan Caplan, Esq., DLA Piper LLP (US)